A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 280 participants.

Also called NCT05179876

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 280 participants (planned count) (from the registry)
Sponsor
  • Actelion Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05179876
  • EudraCT 2021-002297-11
  • EU CT 2023-506791-27-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Belarus, Belgium, Bulgaria, China, Hungary, Poland, Russia, South Africa, South Korea, Taiwan, Thailand, Ukraine, Vietnam (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05179876. Non-randomized; no masking; primary purpose treatment. Start 2022-05-04 (actual); primary completion 2027-01-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option
Acronym
PLATYPUS
Condition
Hypertension, Pulmonary
Intervention (Drug)
Macitentan
Intervention (Drug)
Selexipag
Intervention (Drug)
Macitentan/Tadalafil FDC
Lead sponsor
Actelion (class: industry)

Record details

Record id
cardio:ct-nct05179876
Content hash
699a31407a9740155c89830848b109ae6dbe5e4c5fdf22b1137478e32889f5d0